FilingReader Intelligence
Maccura Biotech streamlines operations with asset sales, restructuring
June 12, 2025 at 05:10 AM UTC•By FilingReader AI
Maccura Biotechnology (SZSE:300463) announced a series of strategic moves aimed at streamlining operations and enhancing its core business. The company will sell its 51% stake in Shandong Maccura Biotechnology to Han Siguang for a consideration of CNY17,412,879.00. Maccura will establish an office in Shandong to manage and expand its distribution network in the region.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
The Board of Supervisors' Verification Opinion on Terminating the Implementation of the 2024 Restricted Stock Incentive Plan and Repurchasing and Cancelling the First Category of Restricted Stocks and Cancelling the Second Category of Restricted Stocks and Adjusting the Repurchase Price of the First Category of Restricted StocksJune 11, 2025 at 08:00 AM UTC
Announcement on Termination of Implementation of 2024 Restricted Stock Incentive Plan and Repurchase and Cancellation of Class I Restricted Stocks and Cancellation of Class II Restricted StocksJune 11, 2025 at 08:00 AM UTC
Announcement on Reducing Registered Capital and Amending the Articles of AssociationJune 11, 2025 at 08:00 AM UTC
Announcement on the transfer of all equity interests in a holding subsidiaryJune 11, 2025 at 08:00 AM UTC
News Alerts
Get instant email alerts when Maccura Biotechnology publishes news
Free account required • Unsubscribe anytime